Markets:

Overview

News

Currencies

International

Treasuries

iShares Biotechnology ETF (NQ:IBB)

215.15 +4.32 (+2.05%)

Streaming Delayed Price Updated: 10:27 AM EDT, Aug 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about iShares Biotechnology ETF

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

28 29 Next >

Does the Nasdaq 100 Index Have a Chokehold on the Stock Market? ↗

April 20, 2022

Wednesday, the stock market stuck with its choppy trend.

Via Talk Markets

The Daily Biotech Pulse: Windtree Jumps On Istaroxime Data, Arcturus' COVID-19 Vaccine Trial Data, FDA Rejects Teva's Schizophrenia Med, Otonomy Aces Hearing Loss Study ↗

April 20, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Real Motion Shows Hidden Momentum in the Russell 2000 and S&P 500 ↗

April 19, 2022

While the market is choppy and traders should be extra careful, if Wednesday shows follow-through in both price and momentum, we can watch for Tuesday’s rally to continue.

Via Talk Markets

The Daily Biotech Pulse: Regeneron Acquires Checkmate Pharma, Moderna's Bivalent Booster COVID-19 Vaccine Update, Priority Review For AstraZeneca's Enhertu ↗

April 19, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More ↗

April 17, 2022

Biotech stocks retreated in the week ending April 14, lock-stepping with the broader market. The news flow was light during the holiday-shortened week and ahead of the imminent first-quarter reporting...

Via Benzinga

Will the Market Pick a Direction On Monday? ↗

April 14, 2022

When the indices are tough to read, it can help to watch other symbols like JNK and VXX.

Via Talk Markets

The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More ↗

April 14, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More ↗

April 13, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal

Via Benzinga

Why We Bought Invesco Agricultural Fund (DBA) ↗

April 12, 2022

One problem with soft commodities is when countries need more food, there is no instant fix, as it takes time to grow. Along with drought and other potential issues, it could take another 2 to 3 years...

Via Talk Markets

The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More ↗

April 12, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More ↗

April 10, 2022

Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion.

Via Benzinga

Layoffs at Bluebird Bio Highlight the Current Struggles of Biotech Picks ↗

April 08, 2022

Cash will be king in biotech picks like BLUE stock as governments slow approvals and reimbursements of new gene therapies.

Via InvestorPlace

The Daily Biotech Pulse: Pfizer Goes Shopping, AstraZeneca Inks Bispecific Antibody Deal, Aptinyx Faces Clinical Study Setback, Erytech Jumps On Data And More ↗

April 07, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Keep Eyes on Momentum in the Small-Cap Index and The Biotech Space ↗

April 06, 2022

If BIIB can clear and close over roughly $212, it would confirm that price and momentum agree and show it's potentially ready for another move higher.

Via Talk Markets

The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy ↗

April 06, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel ↗

April 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Regional Banking (KRE) Holds onto Support and Momentum ↗

April 04, 2022

If the regional banking space can make a quick turnaround Silvergate Capital could be one company that leads the way higher.

Via Talk Markets

The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight ↗

April 03, 2022

Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that...

Via Benzinga

If The Market Holds Watch Bitcoin And The Biotech Space ↗

April 03, 2022

The past week was a chop fest in the major indices with large intraday price swings. While the 3 major indices closed roughly flat on Friday, the Russell 2000 made a late-day turnaround ending up over...

Via Talk Markets

March Madness, Revisiting The First Quarter ↗

April 03, 2022

You might be surprised to learn that betting on March Madness this year topped $3.1 billion. That number only covers the legitimate bracket contests and betting. I am confident that it is much higher...

Via Talk Markets

Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates ↗

April 01, 2022

Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with...

Via Benzinga

The Daily Biotech Pulse: SELLA In-licenses Oncology Asset, Merck's Pneumococcal Vaccine Review Extended, Arc Biopharma COVID Drug Flunks Mid-Stage Study ↗

April 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall ↗

March 31, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Has the Small-Cap Index (IWM) Tricked Us? ↗

March 30, 2022

IWM closing underneath its breakout level at $209 on Wednesday does not look good.

Via Talk Markets

The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict ↗

March 30, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Commodities Make a Quick Turnaround ↗

March 29, 2022

Tuesday, many commodity ETFs gapped lower while the major indices gapped up.

Via Talk Markets

The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia ↗

March 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO ↗

March 25, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More ↗

March 27, 2022

Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.

Via Benzinga

The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL ↗

March 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

28 29 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.